The global in vitro diagnostics market is on track for sustained expansion through the end of the decade, with newly released research valuing the market at USD 85.96 billion in 2023 and projecting growth to USD 144.11 billion by 2031 — a compound annual growth rate of 6.78%. The rising global burden of chronic disease, combined with an accelerating shift toward personalized and preventive healthcare, is driving demand for tests capable of detecting and monitoring conditions earlier and more precisely than ever before.
In vitro diagnostics encompass a broad range of medical tests that analyze biological samples — including blood, urine, and tissue — outside the human body to diagnose disease, monitor health status, and evaluate treatment effectiveness. The category spans instruments, reagents, test kits, and software systems, with applications extending across oncology, cardiology, infectious disease, and genetic testing. As precision medicine gains traction globally, IVD technology is increasingly viewed as foundational infrastructure for modern healthcare delivery rather than a peripheral diagnostic tool.
Chronic Disease Prevalence Anchors Long-Term Growth
The market’s core growth driver remains the escalating prevalence of chronic conditions such as diabetes, cardiovascular disease, and cancer, which is intensifying demand for early detection and ongoing monitoring solutions. According to the World Health Organization, noncommunicable diseases account for 74% of global deaths, with 86% of premature deaths occurring in low- and middle-income countries — underscoring the urgent need for accessible, affordable diagnostic infrastructure capable of catching disease earlier in its progression, when treatment is most effective and least costly.
Technological Innovation Improving Speed and Accuracy
Continuous advancement in diagnostic technology is directly translating into faster, more accurate testing processes that improve patient outcomes while optimizing laboratory workflows. These improvements are simultaneously supporting the broader shift toward personalized medicine, as more precise diagnostic data enables clinicians to tailor treatment plans to individual patients. At the November 2024 MEDICA trade event, diagnostics firm Fapon showcased a suite of total IVD solutions spanning chemiluminescence immunoassay, next-generation sequencing, and PCR applications — illustrative of the breadth of innovation currently being brought to market.
A lack of standardization across rapid diagnostic tests remains a notable industry challenge, contributing to variability in results and undermining clinical confidence in certain test categories. Industry stakeholders are increasingly focused on establishing global standards for test design and performance validation. In a step toward addressing this gap, Saphetor SA received European CE mark approval in July 2024 for its VarSome Clinical platform, confirming compliance with the EU’s In-Vitro Diagnostic Medical Devices Regulation for next-generation sequencing analysis in clinical genomics.
AI Integration and Disease Surveillance Define Industry Trends
Artificial intelligence and machine learning are increasingly central to how diagnostics companies are enhancing test accuracy and automating complex data analysis. These technologies enable more efficient processing of large diagnostic datasets, improving sensitivity and specificity while reducing diagnostic errors that could otherwise delay treatment. Roche’s September 2024 expansion of its Digital Pathology Open Environment — incorporating more than 20 AI algorithms from eight new collaborators — reflects the scale at which diagnostic firms are now embedding machine learning into core clinical workflows to support precision oncology.
Global health surveillance needs are also reshaping the competitive landscape, as the rise of infectious disease outbreaks continues to underscore the value of rapid, accurate detection tools. In October 2024, diagnostics firm Abionic received FDA clearance for its rapid sepsis detection test, addressing a critical need for timely intervention in life-threatening infections — a clear example of how rapid diagnostic innovation is directly translating into improved patient outcomes.
Immunoassays and Instruments Lead Segmentation
By product type, instruments led the market in 2023 with USD 34.65 billion in revenue, reflecting rising demand for precision, speed, and automation across healthcare settings, with molecular diagnostics instruments gaining particular traction for their ability to detect genetic variation and support personalized treatment.
By technology, immunoassays secured the largest share at 30.29% in 2023, valued for their ability to deliver rapid, cost-effective results across a wide range of conditions, from infectious disease to cancer biomarkers. By application, infectious diseases are expected to be the fastest-growing segment, expanding at a CAGR of 7.48%, as molecular diagnostics continue to improve early pathogen identification and support global disease containment efforts.
North America Leads, Asia-Pacific Set for Fastest Growth
North America accounted for approximately 35.60% of global market revenue in 2023, worth USD 30.60 billion, supported by advanced healthcare infrastructure, high adoption of innovative diagnostic technology, and substantial healthcare spending. Stringent FDA regulatory oversight continues to reinforce confidence in diagnostic quality and outcomes across the region.
Asia-Pacific is projected to be the fastest-growing region, expanding at a CAGR of 7.81% through 2031. Rapid economic development, improving healthcare infrastructure, and a large, diverse population with rising rates of both infectious and chronic disease are fueling regional demand, with countries including China, India, and Japan accelerating adoption of point-of-care and molecular diagnostic technologies.
Competitive Landscape
Leading players in the space include F. Hoffmann-La Roche, Siemens Healthcare, Abbott, Danaher Corporation, Thermo Fisher Scientific, Becton Dickinson, Bio-Rad Laboratories, Sysmex, QuidelOrtho, and bioMérieux, with competitive strategy centered on R&D investment, strategic partnerships, and product innovation. In a notable August 2024 development, Unilabs and C2N Diagnostics partnered to expand access to blood-based Alzheimer’s disease testing across Europe, the Gulf region, and Latin America, aiming to advance early diagnosis for cognitive disorders on a global scale.
Outlook
With chronic and infectious disease burdens continuing to grow worldwide and diagnostic technology advancing rapidly on the back of AI integration, the in vitro diagnostics market is positioned for durable, high-single-digit growth through 2031. Industry stakeholders expect continued expansion of point-of-care testing and molecular diagnostics to remain central to how healthcare systems address both routine screening and emerging global health threats.
